Change over period: —
NSE · AGARWALEYE
AGARWALEYE
-2.0% from the 52-week high · +35.2% above the low
Dr Agarwal's Health Care Ltd provides ophthalmic care, diagnostic services, and medical treatments. The company operates a network of clinics, focusing on patient care, accessibility, and advanced eye health solutions.
The short version. AGARWALEYE reported revenue of ₹655 crore for Sep 2026, up 31.3% from a year earlier. Net profit was ₹55 crore (up 83.3% year on year). Return on equity was 6.6% in Mar 2026. Promoter holding was 32.33% in Sep 2026, down 0.12 points over 8 quarters.
1 · The price
How has the stock traded?
AGARWALEYE trades 2.0% below its 52-week high and 35.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹655 cr.
Sep 2026 net profit of ₹55 cr.
2.4 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 655 | 614 | 564 | 530 | 499 | 487 | 460 | 431 |
| Net profit | 55 | 45 | 40 | 34 | 30 | 30 | 33 | 22 |
| Net margin % | 8.4 | 7.4 | 7.0 | 6.4 | 6.0 | 6.2 | 7.1 | 5.2 |
| EPS (₹) | 1.73 | 1.43 | 1.25 | 1.07 | 0.94 | 0.95 | 1.03 | 0.71 |
Annual
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | 2080 | 1711 |
| Net profit | 133 | 83 |
| Net margin % | 6.4 | 4.9 |
| EPS (₹) | 4.2 | 2.64 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.6% in Mar 2026; debt to equity is 0.08.
Profitability · 2 years
Returns and margins
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Return on equity % | 6.6 | 4.5 |
| Return on capital % | 9.7 | 8.4 |
| EBITDA margin % | 29.0 | 28.4 |
| Net margin % | 6.3 | 4.8 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 0.12 pts over 8 quarters.
Down 7.41 pts over 8 quarters.
Up 10.77 pts over 8 quarters.
+5 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 32.45 | 32.45 | 32.42 | 32.42 | 32.39 | 32.36 | 32.34 | 32.33 | -0.12 |
| FII | 56.97 | 60.62 | 59.26 | 58.13 | 58.06 | 57.94 | 57.96 | 49.56 | -7.41 |
| DII | 5.1 | 5.21 | 6.44 | 7.92 | 7.78 | 7.83 | 7.72 | 15.87 | +10.77 |
| Public | 5.49 | 1.72 | 1.88 | 1.52 | 1.77 | 1.87 | 1.98 | 2.24 | -3.25 |
Mutual fund holdings · Oct 2026
41 schemes hold this stock
36 the month before.
- Invesco India Pharma and Healthcare Fund7.93% of NAV
- MOTILAL OSWAL SMALL CAP FUND3.33% of NAV
- Invesco India Consumption Fund2.99% of NAV
- ICICI Prudential Healthcare Fund2.77% of NAV
- LIC MF HEALTHCARE FUND2.69% of NAV
- Invesco India Multi cap Fund2.42% of NAV
- Invesco India Small cap Fund2.38% of NAV
- LIC MF SMALL CAP FUND1.9% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AGARWALEYE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about AGARWALEYE
What is the AGARWALEYE share price?
AGARWALEYE (AGARWALEYE) last closed at ₹553.10, up 0.66% on the day. Its 52-week range is ₹406.55 to ₹560.70.
What is the market cap of AGARWALEYE?
AGARWALEYE has a market capitalisation of about ₹17,421 crore. Its price-to-earnings ratio is 102.9.
How are AGARWALEYE's latest results?
AGARWALEYE reported revenue of ₹655 crore for Sep 2026, up 31.3% from a year earlier. Net profit was ₹55 crore (up 83.3% year on year). Return on equity was 6.6% in Mar 2026. Promoter holding was 32.33% in Sep 2026, down 0.12 points over 8 quarters.
Who owns AGARWALEYE?
As of Sep 2026, shareholding was: Promoter 32.33%, FII 49.56%, DII 15.87%, Public 2.24%.
How many mutual funds hold AGARWALEYE?
41 mutual fund schemes held AGARWALEYE in October 2026. That compares with 36 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.